Understand the source comparison
KPV vs LL-37: Head-to-Head Research Comparison
Primary Mechanism MC1R-mediated NF-κB suppression in epithelial and immune cells Direct membrane disruption + FPRL1-mediated immune cell recruitment KPV for targeted anti-inflammatory studies; LL-37 for antimicrobial + immune coordination Antimicrobial Activit
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Mechanism
- MC1R-mediated NF-κB suppression in epithelial and immune cells
- Direct membrane disruption + FPRL1-mediated immune cell recruitment
- KPV for targeted anti-inflammatory studies; LL-37 for antimicrobial + immune coordination
- Antimicrobial Activity
- None. No direct pathogen killing
- Broad-spectrum: Gram+, Gram−, fungi; MIC 1–32 μg/mL
- LL-37 required for studies measuring pathogen clearance
- Tissue Specificity
- High. Gut epithelium, limited systemic distribution
- Moderate. Skin, lung, mucosa; broader systemic presence
- KPV for GI-focused models; LL-37 for multi-tissue or wound research
- Anti-Inflammatory Effect
- 40–60% reduction in TNF-α, IL-6 in colitis models
- 20–40% cytokine modulation; primarily chemotactic rather than suppressive
- KPV delivers stronger direct anti-inflammatory signal
- Study Design Fit
- IBD models, epithelial barrier research, oral delivery protocols
- Wound healing, infection clearance, immune recruitment, topical application
- Match peptide to endpoint. Inflammation resolution vs pathogen elimination
- Storage & Handling
- Reconstitute in bacteriostatic water; stable 28 days at 2–8°C
- Identical post-reconstitution protocols for both peptides